[go: up one dir, main page]

WO1999018814A1 - Preparation permettant d'accroitre le statut antioxydant de cellules - Google Patents

Preparation permettant d'accroitre le statut antioxydant de cellules Download PDF

Info

Publication number
WO1999018814A1
WO1999018814A1 PCT/NL1997/000662 NL9700662W WO9918814A1 WO 1999018814 A1 WO1999018814 A1 WO 1999018814A1 NL 9700662 W NL9700662 W NL 9700662W WO 9918814 A1 WO9918814 A1 WO 9918814A1
Authority
WO
WIPO (PCT)
Prior art keywords
mixture
preparation according
antioxidant
antioxidants
carotenoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL1997/000662
Other languages
English (en)
Inventor
Andries Dirk Siemensma
Marcellinus Jacobus Johannes Hakkaart
Hendrik Jan Zwier
Albert Johan Zwijgers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Givaudan Nederland Services BV
Original Assignee
Quest International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest International BV filed Critical Quest International BV
Priority to AU54169/98A priority Critical patent/AU5416998A/en
Publication of WO1999018814A1 publication Critical patent/WO1999018814A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A23L5/40—Colouring or decolouring of foods
    • A23L5/42—Addition of dyes or pigments, e.g. in combination with optical brighteners
    • A23L5/43—Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives
    • A23L5/44—Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives using carotenoids or xanthophylls
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a preparation for the enhancement of the antioxidant status of cells which comprises a mixture of antioxidants. More particularly, the present invention relates to the application of a mix of naturally occurring antioxidants having antioxidant properties in nutrient compositions including food products, dietary/foods, food supplements, pharma- ceutical compositions and in cell, tissue, culture and fermentation media.
  • Carotenoids work in concert within a cascade of antioxidants including vitamin E and C in the protection of cells against oxidants such as reactive oxygen species (ROS) including free radicals.
  • ROS reactive oxygen species
  • Cells are exposed to ROS as a consequence of the involvement of oxygen in metabolic processes in cells.
  • Mammals, e.g. humans, can also be exposed to oxidants as a result from e.g. pollution of air with a variety of oxidants such as ozone and oxides of nitrogen. Exposure of the skin to sunlight results in the formation of ROS in the skin.
  • ROS age-related macular degeneration
  • ROS such as singlet oxygen, superoxide, hydroxyl and nitric oxide, hydrogen peroxide, hypochlorous acid and peroxynitrite
  • ROS can be physiologically useful, but they can also cause damage under certain circumstances.
  • a significant amount of ROS is generated during mitochondrial oxidative phosphorylation.
  • Photolytic degradation of nitrogen dioxide by sunlight liberates oxygen atoms which can combine with molecular oxygen to form ozone.
  • the oxidants ozone and nitrogen dioxide have a stimulating role in the pathogenesis of various lung diseases including chronic bronchitis, emphysema and lung cancers.
  • Sunlight exposure of the skin results in skin injury.
  • the short-term effects include sunburn and tanning whereas cumulative UV exposure results in photoaging and increased risk of skin cancer.
  • At least a portion of the adverse effects seem to be mediated by ROS which causes lipid peroxidation and cellular damage in skin tissues.
  • Oxidative stress can have multiple effects. It can induce defence systems, and render tissues more resistant to subsequent insult. If oxidative stress is excessive or if defence and repair responses are inadequate, such mechanisms may cause cell injury such as oxidative damage to essential proteins, lipid peroxidation, DNA strand breakage and base.
  • antioxidant status The balance between antioxidants and (pro)oxidants in living organisms is defined as the antioxidant status. This balance is dynamic and, in the human body, is tipped slightly in favour of oxidation, as evidenced by ongoing damage of DNA, lipids, carbohydrates, proteins, uric acid, etc.
  • the mammalian body has been adapted to this slight imbalance by the presence of repair mechanisms.
  • gradual and modest increase in oxidation induces production of endogenous antioxidants, thus providing a type of feedback-regulation mechanism.
  • Oxidative stress a serious imbalance favouring oxidation, is said to result from excessive production of ROS or from weakening of the antioxidant defense system. Severe oxidative stress may be important for good health and prevention of disease.
  • AGE's advanced glycation end products
  • AGE's the irreversibly formed products from non-enzymatic glycation and oxidation of proteins and lipids, occurring with ageing can trigger a series of cellular events such as cellular oxidative stress, expression of leucocyte adhesion molecules, endothelial trans- migration of monocytes and smooth muscle cell chemotaxis which are all considered as important prelesional events in the atherogenesis process .
  • the antioxidant status is determined by factors affecting the antioxidant system and/or by the production of ROS. Diet, food and alcohol , more than any other factors , directly affect both the antioxidant system - by supplying dietary antioxidants and cofactors of endogenous antioxidants - and production of ROS.
  • Major components of the antioxidant system derived from the diet comprising fruit and vegetables include carotenoids, tocopherols and tocotrienols (vitamin E) , ascorbate (vitamin C) , polyphenols including flavonoids etc.
  • Other nutrients are essential for normal function of endogenous systems; minerals Cu, Mn, Zn, Se and Fe are important cofactors of antioxidant enzyme systems.
  • Cell and tissue levels of dietary antioxidants are affected directly by the amount and food com- position of the diet and by supplementation.
  • the amount of fruit and vegetables consumed in the western world is much lower than is preferred for the protection against degenerative diseases associated with oxidative stress.
  • One of the protecting effects of fruit and especially of vegetables is its deliverance of antioxidants such as carotenoids. Therefore, health authorities in the western world recommend higher intakes.
  • the US Department of Agriculture / Department of Health and Human Services recommended as part of their food guidance systeme that the daily diet include two to three servings of fruit and three to five servings of vegetables (Dietary Guidelines for Americans, Home and Garden Bulletin No 232. Washington DC: Govt Printing Office, 1980).
  • the current trend is an even lower con- sumption of fruit and vegetables. In the US only 9% of the population actually consumes these recommended servings (Patterson et al. , Am. J. Publ. Health, 80_, 1443-1449 [1990]).
  • antioxidants derived from fruit and vegetables should be added to foods, food supplements or pharmaceutical preparations to overcome this problem. From the recommended daily intake of about 400 to 500 g of fruit .and vegetables it can be estimated that about 6 to 10 mg of carotenoids in total is consumed.
  • W0 97/06697 discloses a food product comprising natural components which increase the antioxidant status in the blood plasma of the consumer of the food product.
  • This food product comprises antioxidants and/or antioxidant vitamins and preferably a mixture of at least two of these antioxidants and/or antioxidant vitamins, said antioxidants and/or antioxidant vitamins being preferably selected from ⁇ -tocopherol (vitamin E) , ascorbic acid
  • the food product may comprise in particular per amount of the average daily consumed amount of the food product 30- 100 mg of ⁇ -tocopherol and/or 120-600 mg of ascorbic acid and/or 2- 18 mg of - a mixture of - carotenoids and/or 0.5 ⁇ 2.5 g of - a mixture of - tea polyphenols and/or 25-125 mg of - a mixture of - polyphenols not being derived from tea.
  • W096/39869 also discloses a food product containing a blend of antioxidants and a edible second component selected from carbohydrates, fats and proteins, wherein said antioxidants may be nutritive antioxidants such as provitamin A carotenes, vitamin C and vitamin E or non-nutritive antioxidants such as non-provitamin A carotenes and antiinflammatory agents.
  • said antioxidants may be nutritive antioxidants such as provitamin A carotenes, vitamin C and vitamin E or non-nutritive antioxidants such as non-provitamin A carotenes and antiinflammatory agents.
  • W0 96/40092 discloses the pharmaceutical application of the carotenoids lutein and zeaxanthin in the treatment or prophylaxis of disease of the macula, more particularly the age-related macular degeneration.
  • W096/19215 discloses a method for the prevention or treatment of atherosclerosis in a mammal, wherein an effective amount of natural tocopherol and natural carotene is administered to said mammal.
  • the prior art therefore discloses mixtures of naturally occurring antioxidants including naturally occurring carotenoids and the use thereof in food products, food supplements and pharmaceutical preparations.
  • mixtures of naturally occurring carotenoids have several disadvantages.
  • oleoresins containing mixtures of carotenoids are also extracted from natural sources and have a large variation of carotenoid crystals and/or amorphous particles having sizes which vary typically from 5 to 300 ⁇ m, whereas the majority of said crystals and/or amorphous particles is in the 200 - 300 ⁇ m range. This high variation in particle size leads to inhomogenicity and instability of the carotenoid blend as the particles may easily agglomerate.
  • the present invention provides a solution for the problems mentioned hereinabove in particular those related to the large variation of the size of carotenoids and/or amorphous particles.
  • the present invention therefore relates to a preparation of an improved mixture of naturally occurring antioxidants having a physical form and particle size which confers stability thereof in products such as food products and does not disrupt the product structure so that bioavailability of the antioxidants is improved, e.g. the care and/or cure of the physiological antioxidant status of a mammal and of prokaryotic and eucaryotic cells.
  • the present invention relates more in particular to a preparation for the enhancement of the antioxidant status of cells which comprises a mixture of antioxidants, wherein the mixture comprises at least (a) two naturally occurring carotenoids, (b) a naturally occurring tocopherol or a derivative thereof, and (c) vitamin C, wherein the naturally occurring carotenoids are in the form of carotenoid containing particles having an average diameter of 0.01 to 100 ⁇ m.
  • the present invention relates to a preparation comprising a mixture of antioxidants, wherein the mixture comprises at least (a) two naturally occurring carotenoids, (b) a naturally occurring tocopherol or a derivative thereof, and (c) vitamin C, wherein the naturally occurring carotenoids are in the form of carotenoid containing particles having an average diameter of 0.01 to 100 ⁇ m.
  • the size of the carotenoid particles influences the bioavailability of the carotenoids.
  • the carotenoids present in the supplemented foods which were part of a normal diet, were absorbed about 4 to 10 times more efficiently than those present in the vegetables in the diet.
  • the amount of carotenoids for supplementing a diet can be 4 to 10 times lower than the amount which is only based on the carotenoid content of vegetables.
  • Bio- markers & Prev., 4, 491-496 [1995]) shows in a 9 days human feeding study that an experimental high vegetable carrots-spinach diet 1 mg ⁇ -carotene in the diet gives an ⁇ -carotene rise of 0.0371 ⁇ mol/L in the blood plasma whereas 1 mg ⁇ -carotene rises the plasma concentration of ⁇ -carotene with 0.0137 ⁇ mol/L.
  • the amounts of carotenoids to supplement the diet by a food or food supplement can be several times lower than amounts simply based on the carotenoid content of vegetables. That means that consumption of only a little amount of the preparation according to the invention can be regarded as equivalent to the consumption of - much higher - amounts of carotenoids as present in fruits and vegetables and that for the prevention of degenerative diseases in normal situations only the consumption of a small amount of the preparation according to the invention is sufficient. In case of enhanced oxidative stress or diseases, the consumed amount of the preparation according to the invention is assumed to be several times higher than under normal situations.
  • the preparation contains at least two naturally occurring carotenoids which are obtained by milling carotenoid extracts in a milling machine such as a ball-milling machine, so that the naturally occurring carotenoids are in the form of carotenoid containing particles having an average diameter of 0.01 to 100 ⁇ m are obtained.
  • the milling is carried out in such a way that the average diameter of the carotenoid containing particles is in the range of 0.1 to 50 um.
  • the preparation containing carotenoid particles having an average diameter of 0.01 to 100 ⁇ m are prepared by blending oleoresins comprising carotenoids and at least the other components (b) and (c) followed by milling in e.g. a ball-milling machine.
  • the agglomerated carotenoids and the large carotenoid crystals are reduced in size.
  • reagglo- meration of the carotenoid particles having an average diameter of 0.01 to 100 ⁇ m is prevented by adding a one or more surface active agents .
  • a suitable and preferred surface active agent is lecithin.
  • the carotenoid particles typically have an average diameter of about 10 ⁇ m within the range of 0.1 to 50 ⁇ m as analyzed by laser size recording. On a routine base the particles can be qualitatively sized by microscopic examination.
  • a stable mixture of carotenoid containing particles as contained by the preparation according to the invention can also be achieved by encapsulating.
  • the process of encapsulation according to the invention involves the following steps: solubilisation and milling, e.g. ball-milling, of carotenoids, dispersion of this solution into an aqueous emulsion base - particle size reduction / further emulsification by high pressure homogenisation.
  • various additional functional antioxidants e.g. ascorbic acid, ascorbic palmitate and tocopherols may be added to enhance the product shelf life.
  • emulsifiers may be added which encapsule the small droplets of carotenoids and forming the phase interface.
  • the emulsifiers used are preferably modified starch, gelatin from various sources such as fish gelatin, gum arabic and milk proteins. In this way encapsulated blends of carotenoids and/or curcumin can be obtained wherein the particles have an average diameter of 0.1 to 10 ⁇ m.
  • the invention further provides water soluble emulsions of carotenoids which are made by high pressure homogenisation.
  • the particle size is on average in the range of 0.5 - 2.0 um.
  • the emulsified mixtures or blends of carotenoids as obtained by encapsulation may optionally contain curcumin.
  • the preparation according to the invention can be used in soft gelatine capsules which are highly stable and non leaking capsules.
  • the preparation according to the invention may also be used in fat, low or non fat foods in which the preparation is homogenously and stably distributed.
  • the uptake of the carotenoids in the highly bioavailable form as disclosed herein combined with the components (b) and (c) leads to an enhanced antioxidant management in the cells and tissues and, as a consequence, to less oxidative damage.
  • the levels at which the preparation is applied in various products can be relatively low in comparison with levels of the normally used antioxidant mixtures derived from fruit and vegetables .
  • the component (a) of the preparation according to the invention is preferably selected from the group of carotenoids comprising a ⁇ -carotene, a ⁇ -carotene, a ⁇ -carotene, lycopene, lutein, zeaxanthin, capsanthin, capsorubin or a mixture thereof, wherein these carotenoids may be in the cis and/or trans configuration. According to the invention, however, these carotenoids are a mixture of cis .and trans isomers.
  • the component (b) of the preparation according to the invention is preferably selected from ⁇ -, ⁇ -, ⁇ -, ⁇ -tocopherol, a mixture of these tocopherols, ⁇ -, ⁇ -, ⁇ -tocotrienol or a mixture of tocotrienols or a mixture of these tocopherols and tocotrienols .
  • the preparation according to the invention preferably comprises also one or more of the following antioxidants: ⁇ one or more antioxidants selected from the group of polyphenols derived from fruits, preferably red fruits and in particular grapes , wherein the polyphenols may be flavonoids .
  • the antioxidants intended here may also be derived from vegetables and products derived thereof such as tea, wine, beer or other fermented beverages and/or products derived thereof .
  • a vitamin B in particular folate, vitamin B 6 , vitamin B 12 or a mixture thereof.
  • an antioxidant selected from spices, herbs, antioxidants derived from natural extracts of fruits and vegetables, or a mixture of at least of two of these antioxidants.
  • a preferred spice is curcumin.
  • a preferred herb is rosemary or tea or a mixture thereof.
  • an antioxidant mineral is selected from selenium, manganese, iron, copper, zinc or a mixture thereof.
  • the antioxidant peptide is preferably gluthatione.
  • the antioxidant protein is preferably catalase, superoxide dismutase, a peroxidase, lactoferrin, transferrin, ferritin, caeruloplasmin, albumin or a mixture thereof, whereas the peroxidase is preferably gluthatione peroxidase, horseradish peroxidase, lactoperoxidase or a mixture thereof, an additional antioxidant selected from uric acid, taurine, cysteine, Coenzym Q, bilirubin, or a mixture thereof. More preferably the preparation comprises as the additional antioxidant uric acid or taurine or a mixture thereof.
  • the preparation according to the invention may be used in a food product or food supplement which preferably comprises an amount of 0.01 to 10 mg of a mixture of at least two naturally occurring carotenoids, said amount being based on the average daily doses of the preparation.
  • the food product or food supplement is contained by a soft gelatine capsule.
  • the preparation according to the invention may be used in a pharmaceutical composition, wherein the preparation preferably contains an amount of 0.01 to 5 mg ⁇ -carotene, said amount being based on the average daily doses of the pharmaceutical composition.
  • the preparation according to the invention may further be used in a cell, tissue, culture or fermentation medium.
  • the carotenoid composition per capsule is 1.9 mg ⁇ -carotene, 3.4 mg ⁇ -carotene and 0.1 mg ⁇ - carotene, 1.9 mg lutein and 0.1 mg zeaxanthin, 2.0 mg lycopene,
  • Vegex® red wine grape polyphenols 80 mg polyphenols derived from grape skins and grape seeds, 10 mg vitamin E,
  • vitamin C ascorbic acid
  • vitamin B-complex including 2 mg vitamin B 6 , 1 ⁇ g vitamin B 12 , 100 ⁇ g folic acid.
  • Vegex ® a registered trademark of Quest International, is a range of vegetable extracts such as mixes of carotenoids, curcumin, polyphenols etc.
  • Vegex ® red wine grape polyphenols 60 mg polyphenols derived from grape skins and grape seeds,
  • vitamin C ascorbic acid (encapsulated) or ascorbyl palmitate
  • vitamin B-complex including 2 mg vitamin B 6 , 1 ⁇ g vitamin B 12 , 100 ⁇ g folic acid.
  • 100 mg Vegex® encapsulated carotenoid mix with particle size of 0.3 to 3 ⁇ m, per tablet is 1.9 mg ⁇ -carotene, 3-4 mg ⁇ - carotene and 0.1 mg ⁇ -carotene, 1.9 mg lutein and 0.1 mg zeaxanthin, 2.0 mg lycopene, - 100 mg Vegex® encapsulated curcumin : 10 mg curcumin,
  • Vegex ® red wine grape polyphenols 40 mg polyphenols derived from grape skins and grape seeds, 10 mg vitamin E,
  • vitamin C ascorbic acid (encapsulated), - 4 mg vitamin B-complex, including 2 mg vitamin B 6 , 1 ⁇ g vitamin B 12> 100 ⁇ g folic acid.
  • the 1000 ml blend of water dispersible carotenoids is composed from 133 ml Vegex ® palm carotene WS2, 700 ml Vegex® lutein WS1, 100 ml Vegex ® lycopene WSR and 66 ml
  • the carotenoid composition of 1000 ml carotenoid blend is 122 mg ⁇ -carotene, 275 mg ⁇ -carotene and
  • Example 6 Vegetable-fruit bar containing the following antioxidant mix: blend of oil soluble carotenoids containing a mix of 0.01 to
  • lycopene 0.06 mg lycopene, - 75 mg Vegex ® red wine grape polyphenols: 30 mg polyphenols derived from grape skins and/or grape seeds,
  • Biopherol ® is a registered trademark of Quest International containing mixtures of natural tocopherols.
  • a cell culture medium for growth and maintenance of anti CD20, a hybridoma cell line was composed on basis of the well known RPMI 1640 medium. This medium was prepared from the RPMI-1640 select kit from Gibco BRL, Life Technologies Inc. Cat No. 17402-017.
  • the eel culture of media medium contains among others free amino acids, glucose, certain minerals, riboflavin, and B vitamins.
  • Vegex ® red wine grape polyphenols 4 mg polyphenols derived from grape skins and/or grape seeds , 0.5 g vitamin E as ⁇ -tocopherol emulgated with e.g. Pluronic F-68 (Life Technologies Inc) and Tween 80, - 0.2 g vitamin C: ascorbic acid or sodium ascorbate, antioxidants such as uric acid (10 mg) , bilirubin (6 mg) , taurine (0.1 g) , albumin (40 mg) , antioxidant peptides, e.g. gluthatione (1 mg) and specific protein hydrolysates (0.1 g) containing small peptides with e.g. aromatic amino acids, - 2 mg zinc.
  • antioxidants such as uric acid (10 mg) , bilirubin (6 mg) , taurine (0.1 g) , albumin (40 mg) , antioxidant peptides, e.g. gluthatione (1 mg) and specific protein hydrolysates (0.1

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne une préparation qui comprend un mélange d'antioxydants, lequel mélange contient au moins les éléments suivants: (a) un mélange d'au moins deux caroténoïdes d'origine naturelle; (b) un tocophérol d'origine naturelle ou un dérivé de celui-ci; et (c) de la vitamine C. Les caroténoïdes d'origine naturelle se présentent sous forme d'un caroténoïde contenant des particules dont le diamètre moyen varie de 0,01 à 100 νm.
PCT/NL1997/000662 1997-10-14 1997-12-03 Preparation permettant d'accroitre le statut antioxydant de cellules Ceased WO1999018814A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU54169/98A AU5416998A (en) 1997-10-14 1997-12-03 Preparation for the enhancement of the antioxidant status of cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97203188 1997-10-14
EP97203188.4 1997-10-14

Publications (1)

Publication Number Publication Date
WO1999018814A1 true WO1999018814A1 (fr) 1999-04-22

Family

ID=8228824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL1997/000662 Ceased WO1999018814A1 (fr) 1997-10-14 1997-12-03 Preparation permettant d'accroitre le statut antioxydant de cellules

Country Status (2)

Country Link
AU (1) AU5416998A (fr)
WO (1) WO1999018814A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2792831A1 (fr) * 1999-04-28 2000-11-03 Bionatec Sarl Composition a destination cosmetique et/ou dietetique comprenant un melange de lycopene et d'extrait de feuille d'olivier
WO2001017519A1 (fr) * 1999-09-08 2001-03-15 Cognis Deutschland Gmbh & Co. Kg Substance de protection solaire a administration orale
EP1086693A1 (fr) * 1999-09-21 2001-03-28 Kyowa Hakko Kogyo Co., Ltd. Compositions conténant de la proanthocyanidine et un dérivé ou sel de la vitamine B6
FR2799345A1 (fr) * 1999-10-12 2001-04-13 Gervais Danone Sa Composition alimentaire ou dietetique contenant plusieurs antioxydants
WO2002096221A3 (fr) * 2001-06-01 2003-01-16 Mars Uk Ltd Regime pour la peau
EP1200075A4 (fr) * 1999-06-15 2003-05-02 Nutri Logics Inc Compositions de nutriments destines a reduire le risque de maladie, traitement associe, et methode de selection des constituants
WO2003092413A1 (fr) * 2002-05-02 2003-11-13 Gardian Cipla (Pty) Ltd Complements alimentaires
WO2003086329A3 (fr) * 2002-04-09 2003-12-11 Boots Co Plc Compositions et methodes de soin de la peau
WO2004012707A1 (fr) * 2002-07-24 2004-02-12 Basf Aktiengesellschaft Suspensions de sels de l'acide ascorbique et leur utilisation en tant qu'antioxydants
EP1637149A1 (fr) * 2004-06-09 2006-03-22 Medifood GmbH Composition diététique pour l'homme
EP2441433A1 (fr) * 2010-10-13 2012-04-18 Vigenent Inc. Composition contenant de la zéaxanthine microbienne et sa préparation
CN105476011A (zh) * 2015-12-27 2016-04-13 刘家容 一种番茄红素软胶囊的制备方法
CN110772493A (zh) * 2019-11-05 2020-02-11 京花健康科技有限公司 一种抗氧化保健软胶囊及其制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2281961A1 (fr) * 1974-08-13 1976-03-12 Hoffmann La Roche Preparations carotenoidiques dispersables dans l'eau et leur procede de preparation
WO1992000019A1 (fr) * 1990-06-26 1992-01-09 Kalamazoo Holdings, Inc. Compositions d'antioxydants a base d'acide ascorbique active utilisees dans la stabilisation de carotenoides, de matieres grasses et d'aliments
WO1993000015A1 (fr) * 1991-06-20 1993-01-07 Kalamazoo Holdings, Inc. Suspensions de particules d'acide ascorbique de dimensions micrometriques, et leur utilisation comme antioxydants
WO1994022322A1 (fr) * 1993-04-01 1994-10-13 Kalamazoo Holdings, Inc. Antioxydants solides microcristallins a base de catechines de the vert, pour lipides
JPH0867666A (ja) * 1994-08-29 1996-03-12 Lion Corp カロチノイド含有粉末製剤及びその製造方法
WO1996019215A1 (fr) * 1994-12-22 1996-06-27 Henkel Corporation Compositions de tocopherol et de beta-carotene
WO1996039869A1 (fr) * 1995-06-07 1996-12-19 Mars, Incorporated Produit alimentaire dietetique
WO1996040092A1 (fr) * 1995-06-07 1996-12-19 The Howard Foundation Carotenoides pharmaceutiquement actifs
WO1997006697A1 (fr) * 1995-08-21 1997-02-27 Unilever N.V. Produits alimentaires contenant un agent antioxydant

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2281961A1 (fr) * 1974-08-13 1976-03-12 Hoffmann La Roche Preparations carotenoidiques dispersables dans l'eau et leur procede de preparation
WO1992000019A1 (fr) * 1990-06-26 1992-01-09 Kalamazoo Holdings, Inc. Compositions d'antioxydants a base d'acide ascorbique active utilisees dans la stabilisation de carotenoides, de matieres grasses et d'aliments
WO1993000015A1 (fr) * 1991-06-20 1993-01-07 Kalamazoo Holdings, Inc. Suspensions de particules d'acide ascorbique de dimensions micrometriques, et leur utilisation comme antioxydants
WO1994022322A1 (fr) * 1993-04-01 1994-10-13 Kalamazoo Holdings, Inc. Antioxydants solides microcristallins a base de catechines de the vert, pour lipides
JPH0867666A (ja) * 1994-08-29 1996-03-12 Lion Corp カロチノイド含有粉末製剤及びその製造方法
WO1996019215A1 (fr) * 1994-12-22 1996-06-27 Henkel Corporation Compositions de tocopherol et de beta-carotene
WO1996039869A1 (fr) * 1995-06-07 1996-12-19 Mars, Incorporated Produit alimentaire dietetique
WO1996040092A1 (fr) * 1995-06-07 1996-12-19 The Howard Foundation Carotenoides pharmaceutiquement actifs
WO1997006697A1 (fr) * 1995-08-21 1997-02-27 Unilever N.V. Produits alimentaires contenant un agent antioxydant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 9620, Derwent World Patents Index; Class B05, AN 96-196556, XP002072436 *
PATENT ABSTRACTS OF JAPAN vol. 096, no. 007 31 July 1996 (1996-07-31) *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543103A (ja) * 1999-04-28 2002-12-17 ブヨナテック エス．ア． リコピンとオリーブ葉エキスとの混合物を含む、美容用及び／又はダイエット用組成物
WO2000066078A1 (fr) * 1999-04-28 2000-11-09 Bionatec S.A. Composition a destination cosmetique et/ou dietetique comprenant un melange de lycopene et d'extrait de feuille d'olivier
FR2792831A1 (fr) * 1999-04-28 2000-11-03 Bionatec Sarl Composition a destination cosmetique et/ou dietetique comprenant un melange de lycopene et d'extrait de feuille d'olivier
US6646013B1 (en) 1999-06-15 2003-11-11 Nutri-Logics Nutrient formulations for disease reduction
EP1200075A4 (fr) * 1999-06-15 2003-05-02 Nutri Logics Inc Compositions de nutriments destines a reduire le risque de maladie, traitement associe, et methode de selection des constituants
AU772825B2 (en) * 1999-09-08 2004-05-06 Cognis Deutschland Gmbh & Co. Kg Sunscreen agent for oral administration
WO2001017519A1 (fr) * 1999-09-08 2001-03-15 Cognis Deutschland Gmbh & Co. Kg Substance de protection solaire a administration orale
EP1086693A1 (fr) * 1999-09-21 2001-03-28 Kyowa Hakko Kogyo Co., Ltd. Compositions conténant de la proanthocyanidine et un dérivé ou sel de la vitamine B6
US6685970B1 (en) 1999-09-21 2004-02-03 Kyowa Hakko Kogyo Co., Ltd. Compositions containing proanthocyanidin and a vitamin B6 derivative or a salt thereof
FR2799345A1 (fr) * 1999-10-12 2001-04-13 Gervais Danone Sa Composition alimentaire ou dietetique contenant plusieurs antioxydants
WO2001026486A1 (fr) * 1999-10-12 2001-04-19 Compagnie Gervais Danone Composition alimentaire ou dietetique contenant plusieurs antioxydants
US8647681B2 (en) 2001-06-01 2014-02-11 Mars, Inc. Skin diet
WO2002096221A3 (fr) * 2001-06-01 2003-01-16 Mars Uk Ltd Regime pour la peau
GB2378133A (en) * 2001-06-01 2003-02-05 Mars Uk Ltd A foodstuff comprising Vitamin C, taurine, curcumin and aloe vera and its use in the control of skin disorders
GB2378133B (en) * 2001-06-01 2005-01-26 Mars Uk Ltd Skin diet
WO2003086329A3 (fr) * 2002-04-09 2003-12-11 Boots Co Plc Compositions et methodes de soin de la peau
WO2003092413A1 (fr) * 2002-05-02 2003-11-13 Gardian Cipla (Pty) Ltd Complements alimentaires
WO2004012707A1 (fr) * 2002-07-24 2004-02-12 Basf Aktiengesellschaft Suspensions de sels de l'acide ascorbique et leur utilisation en tant qu'antioxydants
AU2003250967B2 (en) * 2002-07-24 2009-05-28 Basf Aktiengesellschaft Ascorbic acid salt suspensions and use thereof as antioxidants
EP1637149A1 (fr) * 2004-06-09 2006-03-22 Medifood GmbH Composition diététique pour l'homme
EP2441433A1 (fr) * 2010-10-13 2012-04-18 Vigenent Inc. Composition contenant de la zéaxanthine microbienne et sa préparation
CN105476011A (zh) * 2015-12-27 2016-04-13 刘家容 一种番茄红素软胶囊的制备方法
CN110772493A (zh) * 2019-11-05 2020-02-11 京花健康科技有限公司 一种抗氧化保健软胶囊及其制备方法

Also Published As

Publication number Publication date
AU5416998A (en) 1999-05-03

Similar Documents

Publication Publication Date Title
Schwedhelm et al. Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress
Khadim et al. Antioxidant vitamins and their effect on immune system
EP1212071B1 (fr) Compositions stables de granules contenant de la carotene-xanthophylle et procedes d'utilisation
US7842722B2 (en) Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
US8455004B2 (en) Primary composition comprising a lipophilic bioactive compound
Stahl Macular carotenoids: lutein and zeaxanthin.
EP1448066B1 (fr) Procede de preparation des suspensions de carotenoides finement dispersees a utiliser dans des produits alimentaires
US20070141170A1 (en) Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
EP3973972A1 (fr) Compositions multi-compléments
US20100159029A1 (en) Composition and nutritional supplements for improving ocular health and reducing ocular inflammatory response
EP1447012A1 (fr) Complement nutritionnel destine a traiter la degenerescence maculaire
WO1999018814A1 (fr) Preparation permettant d'accroitre le statut antioxydant de cellules
US20080095757A1 (en) Vitamin c compositions
US20050106219A1 (en) Primary composition comprising a lipophilic bioactive compound
US11090274B2 (en) Formulation and method for supporting retinal health thereby reducing the risk of age-related macular degeneration (AMD)
Mortensen Supplements
Handu et al. Vitamins as Functional Foods and Nutraceuticals
BURRI Lycopene and human health
Ndiamaka Okorie., et al.“Antioxidants Properties of Natural and Synthetic Chemical Compounds: Therapeutic Effects on Biological System
Siems et al. Clinical Use of Carotenoids-Antioxidative Protection versus Prooxidative Side Effects
Maci Increasing Lutein Consumption–Are all Luteins Alike?
Grune Clinical Use of Carotenoids–Antioxidative Protection versus Prooxidative
Guard For blue light protection./Introduction to Eye Guard
Vranešić-Bender Uloga nutraceutika u anti-agingu
MX2008007883A (en) Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA